NASDAQ:GTBP

GT Biopharma Q1 2025 Earnings Results & Report

GT Biopharma logo
$2.96 -0.22 (-6.92%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.75 -0.21 (-7.06%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GT Biopharma missed analyst earnings expectations in its Q1 2025 results, released May 15, 2025. The company reported EPS of -$19.00 versus the -$16.00 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

GT Biopharma EPS Results

Actual EPS
-$19.00
Consensus EPS
-$16.00
Beat/Miss
Missed by -$3.00
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

GT Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

GT Biopharma Q1 2025 Earnings FAQ

GT Biopharma (NASDAQ:GTBP) reported earnings of -$19.00 per share for Q1 2025, missing the consensus estimate of -$16.00. The report was announced on Thursday, May 15, 2025.

GT Biopharma Earnings Headlines

GT Biopharma Reports Third Quarter 2026 Financial Results
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
GT Biopharma Regains Nasdaq Minimum Bid Compliance
See More GT Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GT Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GT Biopharma and other key companies, straight to your email.

About GT Biopharma

GT Biopharma (NASDAQ:GTBP) (NASDAQ: GTBP) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research centers on its TriKE platform, which is designed to direct natural killer (NK) cells toward cancer cells and support their activity using an immune-stimulating signal.

The company’s pipeline includes GTB-3650, a candidate designed to target CD33-expressing blood cancers such as acute myeloid leukemia, and GTB-5550, a candidate targeting B7-H3, a protein found on various solid tumors. These candidates remain in development; GT Biopharma does not have a marketed cancer therapy.

View GT Biopharma Profile